Guardant Complete

Backed by >80 clinical outcomes studies
and >350 peer-reviewed publications.

Explore some of the clinical data and discover how each test
provides insight for critical decisions across
the cancer continuum.

    • Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

      Leighl NB, et al. Clin Cancer Res. 2019

      Read more ›
    • Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer

      Page RD, et al. Clin Lung Cancer. 2022

      Read more ›
    • Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer

      Aggarwal C, et al. JAMA Oncol. 2019

      Read more ›
    • Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)

      Palmero R, et al. J Thorac Onc. 2018

      Read more ›
    • Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

      Cui W, et al. Eur J Cancer. 2022

      Read more ›
    • Minimal Residual Disease Detection Using a Plasma-Only Circulating Tumor DNA Assay in Patients With Colorectal Cancer

      Parikh AR, et al. Clin Cancer Res. 2021

      Read more ›
    • Multiomic, Plasma-Only Circulating Tumor DNA (ctDNA) Assay Identifies Breast Cancer Patients With Minimal Residual Disease (MRD) and Predicts Distant Recurrence (BRandO BiO Study)

      Janni W, et al. AACR meeting. 2022

      Read more ›
    • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients With Advanced Cancers Treated With Immune Checkpoint Blockade

      Zhang Q, et al. Cancer Discov. 2020

      Read more ›
    • Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

      Thompson JC, et al. JCO Precis Oncol. 2021

      Read more ›